학술논문
Omalizumab prevents respiratory illnesses in non‐atopic chronic spontaneous urticaria patients: A prospective, parallel‐group, pilot pragmatic trial
Document Type
article
Source
Clinical and Translational Allergy, Vol 13, Iss 7, Pp n/a-n/a (2023)
Subject
Language
English
ISSN
2045-7022
Abstract
Abstract Background Omalizumab is the recommended treatment for antihistamine‐refractory chronic spontaneous urticaria (CSU) and severe allergic asthma. In addition, it has been shown to reduce the frequency of viral respiratory infections in allergic asthma. Respiratory illness is a known trigger for asthma and CSU. Objectives To explore whether the antiviral effect of omalizumab may be extended to CSU patients independent of their atopic status. Methods We conducted a prospective parallel‐group pilot pragmatic trial including 30 non‐allergic and non‐atopic CSU patients (cases) under omalizumab 300 mg Q4‐weeks (due to refractory to H1‐antihistamines) and 30 age‐matched healthy controls. All CSU patients had to have a weekly urticaria activity score UAS7